These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 13710880)

  • 1. Effect of bretylium tosylate (Darenthin) on pulmonary circulation.
    HALMAGYI DF; COLEBATCH HJ
    Circ Res; 1961 Jan; 9():136-8. PubMed ID: 13710880
    [No Abstract]   [Full Text] [Related]  

  • 2. Effects of brachial arterial infusion of bretylium tosylate on hand blood flow.
    FRENCH EB; MATTHEWS MB
    Clin Sci; 1961 Oct; 21():151-5. PubMed ID: 13895014
    [No Abstract]   [Full Text] [Related]  

  • 3. The influence of intermittent bretylium tosylate (darenthin) on the development of vascular disease in rats with hypertension caused by sodium retention.
    GARDNER DL
    Br J Exp Pathol; 1962 Feb; 43(1):88-92. PubMed ID: 13896894
    [No Abstract]   [Full Text] [Related]  

  • 4. Hypotensive action of bretylium tosylate (darenthin).
    HODGE JV; SMIRK FH
    Am Heart J; 1960 Oct; 60():539-44. PubMed ID: 13714830
    [No Abstract]   [Full Text] [Related]  

  • 5. Studies on a new hypotensive agent: bretylium tosylate.
    GENEST J; DUFAULT G; PIGEON G; DAVIGNON J; BIRON P; TRUDEL J
    Can Med Assoc J; 1960 Apr; 82(17):872-7. PubMed ID: 13827287
    [No Abstract]   [Full Text] [Related]  

  • 6. Selective inhibition of the sympathetic nervous system in man with bretylium tosylate, a new antihypertensive agent.
    FREIS ED; SUGIURA T; LIPTAK D
    Circulation; 1960 Aug; 22():191-7. PubMed ID: 13849851
    [No Abstract]   [Full Text] [Related]  

  • 7. The circul atory effects of bretylium tosylate and guanethidine.
    TAYLOR SH; DONALD KW
    Lancet; 1960 Aug; 2(7147):389-94. PubMed ID: 13837199
    [No Abstract]   [Full Text] [Related]  

  • 8. Clinical and experimental studies on bretylium tosylate, a new hypotensive agent.
    HAYDEN JG; BOAKE WC
    Med J Aust; 1960 Apr; 47(1)():528-32. PubMed ID: 14400312
    [No Abstract]   [Full Text] [Related]  

  • 9. Effects of bretylium tosylate on blood-pressure, cardiac output, and renal function in hypertension.
    DOYLE AE; FRASER JR; SMITH PK
    Br Med J; 1960 Aug; 2(5196):422-5. PubMed ID: 13817928
    [No Abstract]   [Full Text] [Related]  

  • 10. [Influence of bretylium tosylate on renal function in the course of arterial hypertension].
    ZUCCHELLI P; DALMASTRI G
    G Clin Med; 1961 Jan; 42():1-14. PubMed ID: 13788864
    [No Abstract]   [Full Text] [Related]  

  • 11. EFFECT OF GUANETHIDINE AND BRETYLIUM TOSYLATE ON SYSTEMIC AND RENAL HEMODYNAMICS IN ESSENTIAL HYPERTENSION.
    VILLARREAL H; EXAIRE JE; RUBIO V; DAVILA H
    Am J Cardiol; 1964 Nov; 14():633-40. PubMed ID: 14218846
    [No Abstract]   [Full Text] [Related]  

  • 12. [Bretylium tosylate (Darenthin). Report of an experiment on the clinical significance of bretylium tosylate in the treatment of hypertension].
    ZELVELDER WG
    Ned Tijdschr Geneeskd; 1961 Jun; 105():1260-6. PubMed ID: 13788182
    [No Abstract]   [Full Text] [Related]  

  • 13. [Bretylium tosylate (darenthin) a new hypotensive agent].
    CLAUSEN E; HILDEN T; KROGSGAARD AR
    Ugeskr Laeger; 1960 Aug; 122():1103-9. PubMed ID: 13693948
    [No Abstract]   [Full Text] [Related]  

  • 14. [ON HEMODYNAMIC ASPECTS OF ANTIHYPERTENSIVE THERAPY. I. BEHAVIOR OF SYSTEMIC AND PULMONARY CIRCULATION].
    CAMPUS S; ACCATINO G
    Minerva Med; 1964 Sep; 55():2614-8. PubMed ID: 14200479
    [No Abstract]   [Full Text] [Related]  

  • 15. Muscle weakness caused by bretylium tosylate.
    CAMPBELL ED; MONTUSCHI E
    Lancet; 1960 Oct; 2(7154):789. PubMed ID: 13690224
    [No Abstract]   [Full Text] [Related]  

  • 16. Clinical trial of bretylium tosylate (darenthin) in hypertension.
    SHEE JC; THOMAS JE
    Cent Afr J Med; 1960 May; 6():197-8. PubMed ID: 14445704
    [No Abstract]   [Full Text] [Related]  

  • 17. The use of bretylium tosylate (Darenthin) in hypertension.
    DOLLERY CT
    Med Clin North Am; 1961 Mar; 45():429-39. PubMed ID: 13723565
    [No Abstract]   [Full Text] [Related]  

  • 18. Acquired tolerance to bretylium tosylate ("darenthin") in the treatment of hypertension.
    HODGE RL; McPHIE JM
    Med J Aust; 1960 Jul; 47(2)():169-72. PubMed ID: 14402225
    [No Abstract]   [Full Text] [Related]  

  • 19. A sympathetic blocking agent, bretylium tosylate (Darenthin), in the treatment of hypertension.
    CONWAY J; LAUWERS P; HOOBLER SW
    J Lab Clin Med; 1961 Feb; 57():199-205. PubMed ID: 13695220
    [No Abstract]   [Full Text] [Related]  

  • 20. [Action on the circulation of 2-methyl-2-butyl-1,3-propanediol dicarbamate (mebutamate)].
    TACCARDI B; MACCARI M; VALLI A
    Arch Ital Sci Farmacol; 1961 Jul; 11():207-15. PubMed ID: 13918847
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.